Salute e Benessere

Hyper-Personalized Medicine Market Anticipated to Garner $5,886.50 Billion…

Global Hyper-Personalized Medicine Market Forecast Analysis: Global Hyper-Personalized Medicine Market Forecast Analysis: As per the report published by Research Dive, theglobal hyper-personalized medicine market is expected to register a revenue of$5,886.50 billionby 2031 at a CAGR of 11.7% during the forecast period 2022-2031. Segments of the Hyper-Personalized Medicine Market The report has divided the hyper-personalized medicine market into the following...
PR Newswire
25/05/2023

Bio-Gate and OSSIS expand into additional international markets with HyProtect™…

Industrial News Service
25/05/2023

[Latest Report] Wound Care Market is estimated to be US$ 37.15 billion by 2030…

Wound Care refers to the medical treatment and management of wounds, which are injuries to the skin that can occur due to various causes such as cuts, burns, abrasions, surgical incisions, or chronic conditions like ulcers. Proper wound care is crucial for promoting healing, preventing infection, and minimizing complications. Wound Care refers to the medical treatment and management of wounds, which are injuries to the skin that can occur due to various causes such as cuts, burns,...
PR Newswire
25/05/2023

Minutes from Annual General Meeting 2023

All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this release and are available on www.pcibiotech.com. Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO / CFO, rs@pcibiotech.no, Mobile: +47 9400 5757This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.Attachment PCI Biotech Minutes AGM 25 May...
Nasdaq GlobeNewswire
25/05/2023

InSilicoTrials and IBSA Join Forces to Innovate Clinical Trials with Advanced…

Regulatory bodies such as the FDA have encouraged the adoption of in silico techniques, with the Modernization Act - FDAMA- 2.0 bill aiming to streamline drug regulation and bring safe medical products to market faster. The bill allows the use of alternatives methods to animal testing, such in silico testing, before or during the clinical trial phase. In silico studies have emerged as a new model of clinical trials, using algorithms to create computer models and provide clinical data without…
PR Newswire
25/05/2023

Tianlong Helps Hospitals in Thailand Detect Hepatitis Early with Molecular…

"Tianlong can give timely responses both online and offline when we need technical support. We have great confidence in Tianlong's products, and we would welcome more cooperation in the future," said a local hospital representative in Thailand. "Tianlong can give timely responses both online and offline when we need technical support. We have great confidence in Tianlong's products, and we would welcome more cooperation in the future," said a local hospital representative…
PR Newswire
25/05/2023

SKF announces changes to Group Management to further strengthen its commercial…

Rickard Gustafson, President and CEO, says: "To reach our potential, we need to increase our commercial capabilities. These changes in the Group Management team will add a lot of industry experience and new perspectives that will make us stronger as a team." Rickard Gustafson, President and CEO, says: "To reach our potential, we need to increase our commercial capabilities. These changes in the Group Management team will add a lot of industry experience and new perspectives that…
PR Newswire
25/05/2023

Sihoo Unveils the Latest Doro-C300 Ergonomic Office Chair and Launches the "Your…

The Doro-C300 is Made for More Comfortable and Healthier Seating The Doro-C300 is Made for More Comfortable and Healthier Seating Sihoo's Doro-C300 ergonomic office chair is a game-changer for individuals who spend long hours sitting at their desks. Built with advanced ergonomic features, the Doro-C300 provides the ultimate seating comfort and support, ensuring that users remain productive and healthy. The Key Features of the Doro-C300 Include: Pricing and Availability The...
PR Newswire
25/05/2023

Nanomedicine Market to be Worth $410.15 Billion by 2030: Grand View Research…

Read 150 page full market research report, "Nanomedicine Market Size, Share & Trends Analysis Report By Application (Drug Delivery), By Indication (Clinical Oncology, Infectious Diseases), By Molecule Type, By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research. Read 150 page full market research report, " Nanomedicine Market Size, Share & Trends Analysis Report By Application (Drug Delivery), By Indication (Clinical Oncology, Infectious…
PR Newswire
25/05/2023

Debiopharm Partners with Genedata to Digitalize Translational Research

"We have been looking for a digital solution that helps us maximize the value of our R&D data to advance our drug development programs. With Genedata Profiler we have found what we have been searching for," says Carolina Haefliger, Head of Translational Medicine, Debiopharm. "By consolidating large amounts of diverse, multi-source data and enabling our teams to utilize those data easily, Genedata Profiler strengthens our innovative potential, ultimately allowing us to bridge…
PR Newswire
25/05/2023

Orion hosts its Capital Markets Day today, May 25, 2023, in Helsinki

ORION CORPORATIONINVESTOR NEWS25 MAY 2023 at 10.30 EEST Orion hosts its Capital Markets Day today, May 25, 2023, in Helsinki Orion hosts its Capital Markets Day for analysts, institutional investors and other capital market representatives, and media representatives in Helsinki today, May 25, 2023. During the event, company's management will introduce Orion's new business divisions and provide an update on Orion's R&D and drivers for growth and profitability...
Nasdaq GlobeNewswire
25/05/2023

Synapse Medicine and CompuGroup Medical Announce Partnership to Revolutionize…

Current prescribing technologies are becoming obsolete Current prescribing technologies are becoming obsolete Physicians face a growing workload in their daily practice. Much of this workload isn't top-of-license, clinical work like diagnosing and treating. Instead, it's administrative tasks like charting or managing appointments. One area with potential for improvement is the prescription process which poses patient safety challenges due to the constantly evolving complexity of medical...
PR Newswire
25/05/2023

SENISCA shortlisted for 2022/2023 Nature Spinoff prize

SENISCA shortlisted for 2022/2023 Nature Spinoff prizeExeter, UK – 25May 2023:SENISCA, a UK biotechnology company developing RNA based therapeutics to reverse cellular senescence and target the diseases of ageing, today announces that it has been shortlisted for the 2022/2023 Nature Spinoff Prize.The Nature Spinoff Prize is awarded yearly by Nature, the world's leading multidisciplinary science journal, to early-stage university spinoff companies from around the world...
Nasdaq GlobeNewswire
25/05/2023

Strengthening of the cash position thanks to new financing

Press release Ecully , May 25 , 2023 – 8 a.m. Strengthening of the cash position in support ofthe Group's developments“Without compromising on its values, purpose or strategy, the Spineway Group has achieved a genuine transformation of its organization and product offering, which is starting to pay off. Our aim of becoming a benchmark in less invasive spine surgery more than ever requires a strengthening of our range of premium products and services...
Nasdaq GlobeNewswire
25/05/2023

Mendus to participate in upcoming conferences in June 2023

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: Redeye Growth Day Virtual, June 1, 2023Mendus CEO Erik Manting will participate in a live Q&A session on June 1 st. Further details including the on-demand corporate presentation are available via:https://www.redeye.se/events/871323/redeye-growth-day BIO...
Nasdaq GlobeNewswire
25/05/2023

Holding(s) in Company

DXS INTERNATIONAL PLC Holding in Company and Total Voting RightsThe Board of DXS International plc (the “Company”), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification under the DTR that following the Placing announced on 17 May 2023, the following persons have voting rights in the Company as follows: 3. Details of person subject to the notification obligation iv Name Foresight Group LLP...
Nasdaq GlobeNewswire
25/05/2023

Philogen Publishes New Data on a Fibromun-based treatment combination in Science…

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital ZürichL19TNF (also known as Fibromun) is an innovative immunotherapy , discovered and developed by Philogen The new peer-reviewed scientific publicationpresentsrecentpreclinical and translational results obtained in glioblastoma , the most common and most aggressive primary brain...
Nasdaq GlobeNewswire
25/05/2023

Mithra - Letter to Shareholders and Corporate Update

Letter to Shareholders and Corporate Update Access to EUR15 million under amended dealDonesta® U.S. marketing deal is a key near term priorityCDMO strategic options are being explored Donesta ® filing rescheduled for H2 2023 - still expecting U.S. approval in H1 2024Financial update and guidance providedLiege, Belgium ,25 May 2023– 7:30 CEST– Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, (the "Company" or...
Nasdaq GlobeNewswire
25/05/2023

Sandoz Marketing Authorization Applications for proposed biosimilar denosumab…

Submissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, prevention of skeletal related complications in cancer that has spread to the bone and unresectable giant cell tumor of the bone 1,2 Sandoz continues to build its biosimilars portfolio to increase...
Nasdaq GlobeNewswire
25/05/2023

DSM-Firmenich AG announces the successful placement of c. 6.7 million existing…

KAISERAUGST, Switzerland and HEERLEN, Netherlands, May 25, 2023 /PRNewswire/ -- As announced on May 24, 2023, DSM-Firmenich AG (the "Company" or DSM-Firmenich) launched the sale of up to 6,696,477 existing DSM-Firmenich ordinary shares through an accelerated bookbuild offering of shares (the "Share Placement"). KAISERAUGST,Switzerlandand HEERLEN,Netherlands,May 25, 2023/PRNewswire/ -- As announced onMay 24, 2023, DSM-Firmenich AG (the "Company" or DSM-Firmenich)…
PR Newswire
25/05/2023

Major shareholder notification – GN Store Nord A/S

GN Store Nord A/S hereby announces that on May 25, 2023, pursuant to Section 31 of the Danish Capital Markets Act, it has decreased its aggregate holding of treasury shares to below 5% of the share capital and voting rights in GN Store Nord A/S. For further information, please contact: For further information, please contact:Investor RelationsAnne Sofie Staunsbæk Veyhe +45 45 75 85 06 Rune Sandager +45 45 75 92 57Media Relations Steen Frentz Laursen +45 20 65 34 20 About GN ...
Nasdaq GlobeNewswire
25/05/2023

GN Store Nord A/S announces successful completion of directed issue and private…

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURESTHIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFERING MEMORANDUM OR A PROSPECTUS AS DEFINED BY REGULATION (EU) NO. 2017/1129 OF 14 JUNE 2017.GN Store Nord A/S announces successful completion of directed issue and...
Nasdaq GlobeNewswire
25/05/2023

Piramal Pharma Limited Announces Consolidated Results for Q4 and FY2023

Key Highlights for Q4 FY23 and FY23 Nandini Piramal, Chairperson, Piramal Pharma Limitedsaid, " Over the recent years, Q4 has always been the strongest quarter for the Company in terms of revenue contribution and EBITDA margin. This year as well, we have seen a healthy pickup in our Q4 revenues and EBITDA margin compared to previous three quarters of the financial year. Our CDMO business, which had a challenging year, witnessed significant pickup in order bookings in Q4...
PR Newswire
24/05/2023

ERYTECH Announces the Availability of the Documents for its Annual General…

ERYTECHAnnounces the Availability of the Documents for its Annual General Meeting to be held on June 23 , 2023 Cambridge, MA (U.S.) and Lyon (France), May 24 , 2023– ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells , today announced the availability of the documents for its Annual General Meeting to be held...
Nasdaq GlobeNewswire
24/05/2023
Altri  Comunicati